Schulz-Heddergott lab

Curriculum Vitae

• 2021: Habilitation, Venia Legendi for Molecular Medicine
• since 2018: Group Leader, Principal investigator (granted by the DFG), UMG, Germany
• 2013 - 2018: Research Fellow, Molecular Oncology, UMG, Germany
• 2009 - 2012: Postdoc, Molecular Oncology, UMG, Germany
• 2008 - 2009: Postdoc, Sir William Dunn School of Pathology, University of Oxford, UK
• 2008: Ph.D. in Biology, Dept. of Neuroanatomy, UMG, Germany
• 2003: Diploma in Biology, University of Göttingen, Germany

Stipends, Awards and Prizes

• 2022: Claudia von Schilling – Medaille, auf dem Gebiet der Grundlagenforschung
• 2022: Habilitation Prize 2021, UMG, Germany
• 2021: Award Gö-VIP-26 for Nature Communications Jun 29;12(1):4019
• 2018: GZMB Award 2018, University Göttingen - postdoc prize
• 2018: Award Gö-VIP-19 for Cancer Cell 34, 298–314, Aug 13
• 2017: Else-Kröner Cancer Symposium 2017 – poster prize
• 2016 – 2018: Heidenreich von Siebold - Habilitation Stipend, Molecular Oncology, UMG, Germany
• since 2015: selected scientific member of the Else-Kröner-Fresenius Clinician Scientist Kolleg UMG
• 2012 – 2014: selected member of the Dorothea Schlözer Mentoring program, UMG, Germany
• 2012 – 2016: Dorothea Schlözer - Postdoc Stipend, Molecular Oncology, UMG, Germany

Recent publications from our group can be found here:

https://pubmed.ncbi.nlm.nih.gov/?term=Schulz-Heddergott&show_snippets=off&size=200

Selected publications of the last 5 years:

• Klemke L, Blume JP, De Oliveira T and Schulz-Heddergott R. Preparation and Cultivation of Colonic and Small Intestinal Murine Organoids including analysis of gene expression and organoid viability. Bio Protoc. 2022 Jan 20;12(2):e4298.
• Isermann T, Sener ÖC, Stender A, Klemke L, Winkler N, Neesse A, Li J, Wegwitz F, Moll UM and Schulz-Heddergott R. Suppression of HSF1 activity by wildtype p53 creates a driving force for p53 loss-of-heterozygosity. Nature Comm. 2021 Jun 29;12(1):4019.
• Klemke L, Fehlau CF, Winkler N, Toboll F, Singh SK, Moll UM and Schulz-Heddergott R. The gain-of-function p53 R248W allele promotes migration by STAT3 deregulation in human pancreatic cancer cells. Frontiers in Oncology. 2021 Jun 11;11:642603.
• Klemke L, De Oliveira T, Witt D, Stark N, Bohnenberger H, Bucala R, Conradi L-C, Schulz-Heddergott R. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis. Feb 4;12(2):155. 2021.
• Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi L-C, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, and Moll UM. Therapeutic ablation of gain-of-function mutant p53 in colorectal cancer inhibits Stat3-mediated tumor growth and invasion. Cancer Cell. 34(2):298-314. 2018.
• Alexandrova EM, Mirza S, Xu S, Schulz-Heddergott R, and Marchenko ND and Moll UM. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Dis. 8(3). 2017.
• Kramer D, Stark N, Schulz-Heddergott R, Ertych N, Bastians H, Edmunds S, Rossmann L, Moll  UM, Concin N and Dobbelstein, MD. Strong anti-tumor synergy between DNA cross-linking and HSP90 inhibition causes massive premitotic DNA-fragmentation in ovarian cancer cells. ‎Cell Death Differ. 24(2):300-316. 2017.
• Klusmann I, Rodewald S, Müller L, Friedrich M, Wienken M, Li Y, Schulz-Heddergott R, and Dobbelstein M. p53 activity results in DNA replication fork processivity. Cell Rep 17(7):1845-1857. 2016.